France’s Novexel to be acquired by AstraZeneca

Monday 28 December 2009

The value to Big Pharma of novel antibiotics has been underscored by AstraZeneca’s decision to acquire Novexel SA of France for a total cash consideration of up to $505 million. Novexel currently has two anti-infectives in Phase 2 development.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France